Veracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.02), $0.14 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $96.84 million versus the consensus estimate of $93.37 million.

GUIDANCE:

Veracyte sees FY2024 revenue of $402-410 million, versus the consensus of $398.3 million, representing year-over-year growth of 11% to 14% and testing growth of 15% to 18%. This guidance range represents an increase compared to prior guidance of $394 million to $402 million. In addition, the company now expects cash, cash equivalents and short-term investments at the end of the year to be $236 million to $240 million compared to prior guidance of $230 million to $234 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.